Primary and secondary endpoint measures compared by timing to start rivaroxaban administration.

Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (day 7), stratified by AOM resolution at Day 7.

Penelope Abbott (3502094)
Caitlin Frede (14670762)
Wendy C. Y. Hu (10907179)
Sanja Lujic (316280)
Steven Trankle (7048088)
Letitia Campbell (12421633)
Hasantha Gunasekera (8295636)
Robyn Walsh (14670765)
Amanda J. Leach (12415702)
Peter Morris (86687)
Kelvin Kong (10983062)
Jennifer Reath (5572118)

February 2023

Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (d...

Sensitivity analysis using only patients initiated with standard dosage adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban among non-valvular atrial fibrillation (NVAF) patients.

Ping G. Tepper (5920475)
Jack Mardekian (88174)
Cristina Masseria (453142)
Hemant Phatak (444121)
Shital Kamble (5154890)
Younos Abdulsattar (5094779)
William Petkun (5920478)
Gregory Y. H. Lip (195779)

November 2018

Sensitivity analysis using only patients initiated with standard dosage adjusted hazard ratios (HRs)...

Comparison of TB screening and diagnosis in implementation zone prior and during the implementation periods.

Mohammed A. Yassin (340718)
Daniel G. Datiko (252974)
Olivia Tulloch (572084)
Paulos Markos (587292)
Melkamsew Aschalew (214221)
Estifanos B. Shargie (587293)
Mesay H. Dangisso (587294)
Ryuichi Komatsu (141072)
Suvanand Sahu (52452)
Lucie Blok (66093)
Luis E. Cuevas (157332)
Sally Theobald (308823)

May 2013

Comparison of TB screening and diagnosis in implementation zone prior and during the implementati...

Correlation between timing to start rivaroxaban administration and cerebral infarct size.

Masahiro Yasaka (6269139)
Kazuo Minematsu (666282)
Kazunori Toyoda (563887)
Etsuro Mori (159527)
Teruyuki Hirano (6331382)
Toshimitsu Hamasaki (542228)
Hiroshi Yamagami (787880)
Takehiko Nagao (4870924)
Shinichi Yoshimura (359132)
Shinichiro Uchiyama (4870921)

February 2019

Correlation between timing to start rivaroxaban administration and cerebral infarct size.</p

Intra-day and inter-day precision and accuracy values of plasmatic rivaroxaban.

Priscilla Bento Matos Derogis (3723232)
Livia Rentas Sanches (3723250)
Valdir Fernandes de Aranda (3723244)
Marjorie Paris Colombini (3723238)
Cristóvão Luis Pitangueira Mangueira (3723253)
Marcelo Katz (695963)
Adriana Caschera Leme Faulhaber (3723247)
Claudio Ernesto Albers Mendes (3723241)
Carlos Eduardo dos Santos Ferreira (3344150)
Carolina Nunes França (386340)
João Carlos de Campos Guerra (3723235)

February 2017

Intra-day and inter-day precision and accuracy values of plasmatic rivaroxaban.</p

Incidences of major bleeding by timing to start rivaroxaban and cerebral infarct size.

Masahiro Yasaka (6269139)
Kazuo Minematsu (666282)
Kazunori Toyoda (563887)
Etsuro Mori (159527)
Teruyuki Hirano (6331382)
Toshimitsu Hamasaki (542228)
Hiroshi Yamagami (787880)
Takehiko Nagao (4870924)
Shinichi Yoshimura (359132)
Shinichiro Uchiyama (4870921)

February 2019

Incidences of major bleeding by timing to start rivaroxaban and cerebral infarct size.</p

Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for any, major, and clinically relevant Non-Major (CRNM) bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban.

Ping G. Tepper (5920475)
Jack Mardekian (88174)
Cristina Masseria (453142)
Hemant Phatak (444121)
Shital Kamble (5154890)
Younos Abdulsattar (5094779)
William Petkun (5920478)
Gregory Y. H. Lip (195779)

November 2018

Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for any, major, and clinically relev...

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial

August 2016

on behalf of the ROCKET AF Investigators* Background-—Time in therapeutic range (TTR) is a standard ...

Comparison of secondary outcomes variables for base line and end line in control and intervention groups.

Dev Ram Sunuwar (6494717)
Raj Kumar Sangroula (6494720)
Nani Shova Shakya (6494723)
Renu Yadav (500897)
Narendra Kumar Chaudhary (6494726)
Pranil Man Singh Pradhan (763755)

March 2019

Comparison of secondary outcomes variables for base line and end line in control and intervention gr...

Sensitivity analysis—Inverse probability treatment weighting IPTW analyses: Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban among nvaf patients.

Ping G. Tepper (5920475)
Jack Mardekian (88174)
Cristina Masseria (453142)
Hemant Phatak (444121)
Shital Kamble (5154890)
Younos Abdulsattar (5094779)
William Petkun (5920478)
Gregory Y. H. Lip (195779)

November 2018

Sensitivity analysis—Inverse probability treatment weighting IPTW analyses: Adjusted hazard ratios (...

Comparison of sorafenib with other regimens for HCC patients in terms of time to progression (TTP).

Songlin Peng (668024)
Yang Zhao (39052)
Feng Xu (89016)
Changjun Jia (668025)
Yongqing Xu (480309)
Chaoliu Dai (668026)

December 2014

Comparison of sorafenib with other regimens for HCC patients in terms of time to progression (TTP...

Results of the primary and secondary analyses (trazodone versus other antidepressants).

Ruth Brauer (773591)
Wallis C. Y. Lau (3161145)
Joseph F. Hayes (2901962)
Kenneth K. C. Man (6078836)
David P. J. Osborn (309532)
Robert Howard (190740)
Joseph Kim (17521)
Ian C. K. Wong (306894)

February 2019

Results of the primary and secondary analyses (trazodone versus other antidepressants).</p

Incidences of ischemic stroke recurrence and major bleeding by timing to start rivaroxaban. IS, ischemic stroke.

Masahiro Yasaka (6269139)
Kazuo Minematsu (666282)
Kazunori Toyoda (563887)
Etsuro Mori (159527)
Teruyuki Hirano (6331382)
Toshimitsu Hamasaki (542228)
Hiroshi Yamagami (787880)
Takehiko Nagao (4870924)
Shinichi Yoshimura (359132)
Shinichiro Uchiyama (4870921)

February 2019

Incidences of ischemic stroke recurrence and major bleeding by timing to start rivaroxaban. IS, isch...

Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patients.

Ashwin Agarwal (5786984)
Russell P. Hall III (5786987)
Lionel L. Bañez (5786990)
Adela R. Cardones (5786993)

September 2018

Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patien...

Comparison between treatments vs. corresponding Control values at CSR/END midpoint.

Guan-Dong Yang (4169938)
Paul-Michael Agapow (161124)
Gabriel Yedid (161102)

June 2017

Comparison between treatments vs. corresponding Control values at CSR/END midpoint.</p

Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (day 7), stratified by AOM resolution at Day 7.

Penelope Abbott (3502094)
Caitlin Frede (14670762)
Wendy C. Y. Hu (10907179)
Sanja Lujic (316280)
Steven Trankle (7048088)
Letitia Campbell (12421633)
Hasantha Gunasekera (8295636)
Robyn Walsh (14670765)
Amanda J. Leach (12415702)
Peter Morris (86687)
Kelvin Kong (10983062)
Jennifer Reath (5572118)

February 2023

Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (d...

Sensitivity analysis using only patients initiated with standard dosage adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban among non-valvular atrial fibrillation (NVAF) patients.

Ping G. Tepper (5920475)
Jack Mardekian (88174)
Cristina Masseria (453142)
Hemant Phatak (444121)
Shital Kamble (5154890)
Younos Abdulsattar (5094779)
William Petkun (5920478)
Gregory Y. H. Lip (195779)

November 2018

Sensitivity analysis using only patients initiated with standard dosage adjusted hazard ratios (HRs)...

Comparison of TB screening and diagnosis in implementation zone prior and during the implementation periods.

Mohammed A. Yassin (340718)
Daniel G. Datiko (252974)
Olivia Tulloch (572084)
Paulos Markos (587292)
Melkamsew Aschalew (214221)
Estifanos B. Shargie (587293)
Mesay H. Dangisso (587294)
Ryuichi Komatsu (141072)
Suvanand Sahu (52452)
Lucie Blok (66093)
Luis E. Cuevas (157332)
Sally Theobald (308823)

May 2013

Comparison of TB screening and diagnosis in implementation zone prior and during the implementati...

Correlation between timing to start rivaroxaban administration and cerebral infarct size.

Masahiro Yasaka (6269139)
Kazuo Minematsu (666282)
Kazunori Toyoda (563887)
Etsuro Mori (159527)
Teruyuki Hirano (6331382)
Toshimitsu Hamasaki (542228)
Hiroshi Yamagami (787880)
Takehiko Nagao (4870924)
Shinichi Yoshimura (359132)
Shinichiro Uchiyama (4870921)

February 2019

Correlation between timing to start rivaroxaban administration and cerebral infarct size.</p

Intra-day and inter-day precision and accuracy values of plasmatic rivaroxaban.

Priscilla Bento Matos Derogis (3723232)
Livia Rentas Sanches (3723250)
Valdir Fernandes de Aranda (3723244)
Marjorie Paris Colombini (3723238)
Cristóvão Luis Pitangueira Mangueira (3723253)
Marcelo Katz (695963)
Adriana Caschera Leme Faulhaber (3723247)
Claudio Ernesto Albers Mendes (3723241)
Carlos Eduardo dos Santos Ferreira (3344150)
Carolina Nunes França (386340)
João Carlos de Campos Guerra (3723235)

February 2017

Intra-day and inter-day precision and accuracy values of plasmatic rivaroxaban.</p

Incidences of major bleeding by timing to start rivaroxaban and cerebral infarct size.

Masahiro Yasaka (6269139)
Kazuo Minematsu (666282)
Kazunori Toyoda (563887)
Etsuro Mori (159527)
Teruyuki Hirano (6331382)
Toshimitsu Hamasaki (542228)
Hiroshi Yamagami (787880)
Takehiko Nagao (4870924)
Shinichi Yoshimura (359132)
Shinichiro Uchiyama (4870921)

February 2019

Incidences of major bleeding by timing to start rivaroxaban and cerebral infarct size.</p

Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for any, major, and clinically relevant Non-Major (CRNM) bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban.

Ping G. Tepper (5920475)
Jack Mardekian (88174)
Cristina Masseria (453142)
Hemant Phatak (444121)
Shital Kamble (5154890)
Younos Abdulsattar (5094779)
William Petkun (5920478)
Gregory Y. H. Lip (195779)

November 2018

Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for any, major, and clinically relev...

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial

August 2016

on behalf of the ROCKET AF Investigators* Background-—Time in therapeutic range (TTR) is a standard ...

Comparison of secondary outcomes variables for base line and end line in control and intervention groups.

Dev Ram Sunuwar (6494717)
Raj Kumar Sangroula (6494720)
Nani Shova Shakya (6494723)
Renu Yadav (500897)
Narendra Kumar Chaudhary (6494726)
Pranil Man Singh Pradhan (763755)

March 2019

Comparison of secondary outcomes variables for base line and end line in control and intervention gr...

Sensitivity analysis—Inverse probability treatment weighting IPTW analyses: Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban among nvaf patients.

Ping G. Tepper (5920475)
Jack Mardekian (88174)
Cristina Masseria (453142)
Hemant Phatak (444121)
Shital Kamble (5154890)
Younos Abdulsattar (5094779)
William Petkun (5920478)
Gregory Y. H. Lip (195779)

November 2018

Sensitivity analysis—Inverse probability treatment weighting IPTW analyses: Adjusted hazard ratios (...

Comparison of sorafenib with other regimens for HCC patients in terms of time to progression (TTP).

Songlin Peng (668024)
Yang Zhao (39052)
Feng Xu (89016)
Changjun Jia (668025)
Yongqing Xu (480309)
Chaoliu Dai (668026)

December 2014

Comparison of sorafenib with other regimens for HCC patients in terms of time to progression (TTP...

Results of the primary and secondary analyses (trazodone versus other antidepressants).

Ruth Brauer (773591)
Wallis C. Y. Lau (3161145)
Joseph F. Hayes (2901962)
Kenneth K. C. Man (6078836)
David P. J. Osborn (309532)
Robert Howard (190740)
Joseph Kim (17521)
Ian C. K. Wong (306894)

February 2019

Results of the primary and secondary analyses (trazodone versus other antidepressants).</p

Incidences of ischemic stroke recurrence and major bleeding by timing to start rivaroxaban. IS, ischemic stroke.

Masahiro Yasaka (6269139)
Kazuo Minematsu (666282)
Kazunori Toyoda (563887)
Etsuro Mori (159527)
Teruyuki Hirano (6331382)
Toshimitsu Hamasaki (542228)
Hiroshi Yamagami (787880)
Takehiko Nagao (4870924)
Shinichi Yoshimura (359132)
Shinichiro Uchiyama (4870921)

February 2019

Incidences of ischemic stroke recurrence and major bleeding by timing to start rivaroxaban. IS, isch...

Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patients.

Ashwin Agarwal (5786984)
Russell P. Hall III (5786987)
Lionel L. Bañez (5786990)
Adela R. Cardones (5786993)

September 2018

Median prednisone dose among RT patients in their pre and post rituximab phases, and CAT-only patien...

Comparison between treatments vs. corresponding Control values at CSR/END midpoint.

Guan-Dong Yang (4169938)
Paul-Michael Agapow (161124)
Gabriel Yedid (161102)

June 2017

Comparison between treatments vs. corresponding Control values at CSR/END midpoint.</p

Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (day 7), stratified by AOM resolution at Day 7.

Penelope Abbott (3502094)
Caitlin Frede (14670762)
Wendy C. Y. Hu (10907179)
Sanja Lujic (316280)
Steven Trankle (7048088)
Letitia Campbell (12421633)
Hasantha Gunasekera (8295636)
Robyn Walsh (14670765)
Amanda J. Leach (12415702)
Peter Morris (86687)
Kelvin Kong (10983062)
Jennifer Reath (5572118)

February 2023

Severity of symptoms at enrolment into WATCH trial (baseline) compared with primary endpoint time (d...

Sensitivity analysis using only patients initiated with standard dosage adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for inpatient major bleeding during the first 6 months after treatment initiation comparing dabigatran and rivaroxaban vs apixaban among non-valvular atrial fibrillation (NVAF) patients.

Ping G. Tepper (5920475)
Jack Mardekian (88174)
Cristina Masseria (453142)
Hemant Phatak (444121)
Shital Kamble (5154890)
Younos Abdulsattar (5094779)
William Petkun (5920478)
Gregory Y. H. Lip (195779)

November 2018

Sensitivity analysis using only patients initiated with standard dosage adjusted hazard ratios (HRs)...

Comparison of TB screening and diagnosis in implementation zone prior and during the implementation periods.

Mohammed A. Yassin (340718)
Daniel G. Datiko (252974)
Olivia Tulloch (572084)
Paulos Markos (587292)
Melkamsew Aschalew (214221)
Estifanos B. Shargie (587293)
Mesay H. Dangisso (587294)
Ryuichi Komatsu (141072)
Suvanand Sahu (52452)
Lucie Blok (66093)
Luis E. Cuevas (157332)
Sally Theobald (308823)

May 2013

Comparison of TB screening and diagnosis in implementation zone prior and during the implementati...

Primary and secondary endpoint measures compared by timing to start rivaroxaban administration.

Abstract

Extracted data

Primary and secondary endpoint measures compared by timing to start rivaroxaban administration.

Abstract

Extracted data

Related items

Related items